Document:

NATIONAL INSTITUTES OF HEALTH

 

MATERIALS COOPERATIVE RESEARCH

AND DEVELOPMENT AGREEMENT

 

This Materials Cooperative Research and Development Agreement
(“M-CRADA”) has been adopted for use by the Institutes and Centers (“ICs”) of the National Institutes of
Health (“NIH”) for transfers of essential research material(s) from collaborators (hereinafter “Collaborator
Research Material”) not otherwise reasonably available for NIH research. It consists of a copy of the NIH Model M-CRADA,
a Signature Page, a Contacts Page, and a Summary Page. The research plan (“Research Plan”) is attached as Appendix
A and all changes to this model agreement are collected in Appendix B. Appendices A and B are incorporated herein by reference.
This M-CRADA involves no exchange of personnel or of any resources other than as described in Appendix A. This M-CRADA is made
under authority of the Federal Technology Transfer Act, 15 U.S.C. § 3710a, and is governed by its terms.

 

		1.	Lixte Biotechnology Holdings, Inc., hereinafter referred to as “Collaborator”, agrees to transfer to NIH’s
investigator, Richard J. Youle, Ph.D., the following “Collaborator Research Material”: certain compounds
proprietary to Collaborator, as listed under Appendix A.

 

		2.	This Collaborator Research Material will be used solely in connection with the Research Plan by NIH’s investigator in
his/her laboratory under suitable containment conditions.

 

		2(a).	Are the Collaborator Research Materials of human origin?

 ̈
Yes

x
No

 

		2(b).	If Yes in 2(a), were the Collaborator Research Materials collected according to 45 CFR Part 46, “Protection of Human
Subjects?”

 ̈
Yes (Please provide Assurance Number:                         )

 ̈
No

 

		3.	In all oral presentations or written publications concerning the Research Plan, NIH will acknowledge Collaborator’s contribution
of this Collaborator Research Material unless requested otherwise. To the extent permitted by law and unless otherwise directed
by a court or administrative body of competent jurisdiction, each Party agrees to treat in confidence, for a period of three (3)
years from the date of the disclosure, any of the disclosing Party’s written information about this Collaborator Research
Material that is stamped “confidential” or any of the disclosing Party’s oral information about this Collaborator
Research Material that is identified in writing as being confidential within ten (10) days of the oral disclosure, except for:

 

		(a)	information that is publicly known or that becomes publicly available from public sources;

 

		(b)	information that has been made available by the disclosing Party to others without a confidentiality obligation;

 

	NIH M-CRADA	Agreement Ref. No. 2013-0167	MODEL ADOPTED 2006
	Page 1 of 10	Confidential	Revised August 1, 2012

 

    	 

    	 

    

 

		(c)	information that is already known by the receiving Party, or information that is independently created or compiled by the receiving
Party without reference to or use of the provided information; or

 

		(d)	information that relates to potential hazards or cautionary warnings associated with the production, handling, or use of the
subject matter of the Research Plan.

 

NIH may publish or otherwise publicly disclose the
results of the research, but if Collaborator has given confidential information to NIH such public disclosure may be made only
after Collaborator has had thirty (30) days to review the proposed disclosure to determine if it contains any confidential information,
except when a shortened time period under court order or the Freedom of Information Act pertains.

 

		4.	This Collaborator Research Material represents a significant investment on the part of Collaborator and is considered proprietary
to Collaborator. NIH’s investigator therefore agrees to retain control over this Collaborator Research Material, and further
agrees not to transfer the Collaborator Research Material to other people not under her or his direct supervision without advance
written approval of Collaborator. Collaborator reserves the right to distribute the Collaborator Research Material to others and
to use it for its own purposes.

 

		5.	This Collaborator Research Material is provided as a service to the research community. IT IS BEING SUPPLIED TO NIH WITH NO
WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Collaborator makes
no representations that the use of the Collaborator Research Material will not infringe any patent or proprietary rights of third
parties. It is the intention of NIH that Collaborator not be liable for any claims or damages arising from NIH’s use of the
Collaborator Research Material; however, no indemnification is provided or intended.

 

		6.	The NIH shall promptly report to Collaborator in writing each Subject Invention and any patent applications filed thereon resulting
from the research conducted under this M-CRADA that is reported to NIH by its employees. Collaborator agrees to keep all information
provided to Collaborator confidential until the information is published or the patent issues. “Subject Invention”
means any invention, conceived or first actually reduced to practice under this M-CRADA, that is or may be patentable under 35
U.S.C. § 101 or § 161, protectable under 7 U.S.C. § 2321, or otherwise protectable by other types of U.S. or foreign
intellectual property rights.

 

		7.	With respect to Government intellectual property rights to any Subject Invention made solely by an NIH employee(s) or jointly
with Collaborator for which a patent or other intellectual property application is filed, NIH hereby grants to the Collaborator
an exclusive option to elect an exclusive or nonexclusive commercialization license. The license will be substantially in the form
of the appropriate model Public Health Service (PHS) license agreement and will fairly reflect the nature of the Subject Invention,
the relative contributions of the Parties to the Subject Invention and the M-CRADA, a plan for the development and marketing of
the Subject Invention, the risks incurred by Collaborator, and the costs of subsequent research and development needed to bring
the Subject Invention to the marketplace. The field of use of the license will not exceed the scope of the Research Plan. This
option does not apply to Subject Inventions conceived prior to the effective date of this M-CRADA that are reduced to practice
under this M-CRADA, if prior to that reduction to practice, NIH has filed a patent application on the Subject Invention and has
licensed it or offered to license it to a third party.

 

	NIH M-CRADA	Agreement Ref. No. 2013-0167	MODEL ADOPTED 2006
	Page 2 of 10	Confidential	Revised August 1, 2012

 

    	 

    	 

    

 

		8.	To exercise the option of Paragraph 7, Collaborator must submit a written notice to the PHS Patenting and Licensing Contact
identified on the Contacts Information Page (and provide a copy to the NIH Contact for M-CRADA Notices) within three (3) months
after the Collaborator receives written notice from NIH that the patent application has been filed. The written notice exercising
this option will include a completed “Application for License to Public Health Service Inventions” and will initiate
a negotiation period that expires nine (9) months after the exercise of the option. If NIH has not responded in writing to the
last proposal by Collaborator within this nine (9) month period, the negotiation period will be extended to expire one (1) month
after PHS so responds, during which month Collaborator may accept in writing the final license proposal of NIH. In the absence
of Collaborator’s exercise of the option, or upon election of a nonexclusive license, NIH will be free to license the Subject
Invention to others. These time periods may be extended at the sole discretion of NIH upon good cause shown in writing by Collaborator.

 

		9.	Pursuant to 15 U.S.C. § 3710a(b)(1)(A), for Subject Inventions made under this M-CRADA by a NIH employee(s) or jointly
by such employee(s) and employees of the Collaborator under this M-CRADA, and licensed to Collaborator, the Collaborator grants
to the Government a nonexclusive, nontransferable, irrevocable, paid-up license to practice the invention or have the invention
practiced throughout the world by or on behalf of the Government. In the exercise of such license, the Government shall not publicly
disclose trade secrets or commercial or financial information that is privileged or confidential within the meaning of 5 U.S.C.
§ 552(b)(4) or which would be considered as such if it had been obtained from a non-Federal party.

 

		10.	Pursuant to 15 U.S.C. § 3710a(b)(2), for Subject Inventions made solely by Collaborator employees under this M-CRADA,
the Collaborator grants to the Government, a nonexclusive, nontransferable, irrevocable, paid-up license to practice the invention
or have the invention practiced throughout the world by or on behalf of the Government for research or other Government purposes.

 

		11.	Pursuant to 15 U.S.C. § 3710a(b)(l)(B), if NIH grants an exclusive license to a Subject Invention made wholly by NIH employees
or jointly with a Collaborator under this M-CRADA, the Government shall retain the right to require the Collaborator to grant to
a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to use the invention in Collaborator’s
licensed field of use on terms that are reasonable under the circumstances; or if the Collaborator fails to grant such a license,
to grant the license itself. The exercise of such rights by the Government shall only be in exceptional circumstances and only
if the Government determines (i) the action is necessary to meet health or safety needs that are not reasonably satisfied by Collaborator,
(ii) the action is necessary to meet requirements for public use specified by Federal regulations, and such requirements are not
reasonably satisfied by the Collaborator; or (iii) the Collaborator has failed to comply with an agreement containing provisions
described in 15 U.S.C. § 3710a(c)(4)(B). The determination made by the Government under this paragraph is subject to administrative
appeal and judicial review under 35 U.S.C. § 203(b).

 

	NIH M-CRADA	Agreement Ref. No. 2013-0167	MODEL ADOPTED 2006
	Page 3 of 10	Confidential	Revised August 1, 2012

 

    	 

    	 

    

 

		12.	Any dispute arising under this M-CRADA that is not disposed of by agreement of the Principal Investigators shall be submitted
jointly to the signatories of this M-CRADA. If the signatories are unable to jointly resolve the dispute within thirty (30) days
after notification thereof, the Assistant Secretary for Health (or his/her designee or successor) shall propose a resolution. Nothing
in this article shall prevent any Party from pursuing any additional administrative remedies that may be available and, after exhaustion
of such administrative remedies, pursuing all available judicial remedies.

 

		13.	The illegality or invalidity of any provisions of this M-CRADA shall not impair, affect or invalidate the other provisions
of this M-CRADA.

 

		14.	Neither this M-CRADA nor any rights or obligations of any Patty hereunder shall be assigned or otherwise transferred by either
Party without the prior written consent of the other Party.

 

		15.	All notices pertaining to or required by this M-CRADA will be in writing, signed by an authorized representative of the notifying
Party, and delivered by first class, registered, or certified mail, or by an express/overnight commercial delivery service, prepaid
and properly addressed to the other Party at the address designated on the Contacts Information Page, or to any other address designated
in writing by the other Party. Notices will be considered timely if received on or before the established deadline date or sent
on or before the deadline date as verifiable by U.S. Postal Service postmark or dated receipt from a commercial carrier. Notices
regarding the exercise of license options will be made pursuant to Paragraph 8. Either Party may change its address by notice given
to the other Party in the manner set forth above.

 

		16.	By entering into this M-CRADA, the Government does not directly or indirectly endorse any product or service that is or will
be provided, whether directly or indirectly related to either this M-CRADA or to any patent or other intellectual property license
or agreement that implements this M-CRADA by Collaborator, its successors, assignees, or licensees. Collaborator will not in any
way state or imply that the Government or any of its organizational units or employees endorses any product or service. Each Party
agrees to provide proposed press releases that reference or rely upon the work under this M-CRADA to the other Party for review
and comment at least seven (7) days prior to publication. Either Party may disclose the Summary Page to the public without the
approval of the other Party.

 

		17.	Either NIH or Collaborator may unilaterally terminate this M-CRADA at any time by providing written notice at least sixty (60)
days before the desired termination date.

 

		18.	This M-CRADA constitutes the entire agreement between the Parties concerning the subject matter of this M-CRADA and supersedes
any prior understanding or written or oral agreement.

 

		19.	The construction, validity, performance and effect of this M-CRADA will be governed by U.S. federal law, as applied by the
federal courts in the District of Columbia. If any provision in this M-CRADA conflicts with or is inconsistent with any U.S. federal
law or regulation, then the U.S. federal law or regulation will preempt that provision.

 

	NIH M-CRADA	Agreement Ref. No. 2013-0167	MODEL ADOPTED 2006
	Page 4 of 10	Confidential	Revised August 1, 2012

 

    	 

    	 

    

 

		20.	This M-CRADA shall be effective upon execution by the Parties. The term of this M-CRADA is twelve (12) months from execution.
When the Research Plan is completed or twelve (12) months has elapsed, whichever occurs first, or the M-CRADA is terminated, the
Collaborator Research Material will be disposed of as directed by Collaborator.

 

		21.	The provisions of Articles 3, 5-12 and 14 shall survive the termination of this M-CRADA.

 

SIGNATURES BEGIN ON THE NEXT PAGE

 

	NIH M-CRADA	Agreement Ref. No. 2013-0167	MODEL ADOPTED 2006
	Page 5 of 10	Confidential	Revised August 1, 2012

 

    	 

    	 

    

 

SIGNATURE PAGE

 

ACCEPTED AND AGREED

 

By
executing this M-CRADA, each Party represents that all statements made herein are
true, complete, and accurate to the best of its knowledge. Collaborator acknowledges that it may be subject to criminal, civil,
or administrative penalties for knowingly making a false, fictitious, or fraudulent statement or claim.

 

	FOR NIH (IC):	 	 
	 	 	 
	/s/ Walter J. Kovoshetz for Dr. S Landis	 	9/24/2013
	Signature	 	Date
	 	 	 
	WJ Kovoshetz, Deputy Director/NINDS	 	 
	Story C. Landis, Ph.D.	 	 
	Director, National Institute of Neurological Disorders and Stroke	 	 
	 	 	 
	FOR COLLABORATOR:	 	 
	 	 	 
	/s/ John S. Kovach	 	10/18/2013
	Signature	 	Date
	 	 	 
	John S. Kovach. M.D.	 	 
	President, Lixte Biotechnology Holdings, Inc.	 	 

 

	NIH M-CRADA	Agreement Ref. No. 2013-0167	MODEL ADOPTED 2006
	Page 6 of 10	Confidential	Revised August 1, 2012

 

    	 

    	 

    

 

CONTACTS PAGE

 

M-CRADA Notices

 

	For IC:	 	For Collaborator:
	 	 	 
	Laurie Arrants	 	John S. Kovach, M.D.
	Technology Development Coordinator	 	248 Route 25A No. 2
	Building 31, Room 8A52	 	East Setauket, NY 11733
	31 Center Drive, MSC 2540	 	Tel: 631-942-7959
	Bethesda, MD 20892	 	Fax: 631-982-5050
	Tel: 301-435-3112	 	 
	Fax: 301-496-0296	 	 

 

Patenting
and Licensing

 

	For NIH:	 	For Collaborator (if separate from above):
	 	 	 
	Division Director, Division of Technology	 	 
	Development and Transfer	 	 
	NIH Office of Technology Transfer	 	 
	6011 Executive Boulevard, Suite 325	 	 
	Rockville, Maryland 20852-3804	 	 
	Tel: 301-496-7057	 	Tel:
	Fax: 301-402-0220	 	Fax:

 

Delivery of Materials Identified In Article
1

 

For IC: 

IC Contact: Richard J. Youle, Ph.D.

IC Address: SNB, Bldg 35, Room 2C-917, 35 Convent Drive,
MSC 3704, Bethesda, MD 20892-3704

IC Phone Number: 301-496-6628

IC Fax: 301-402-0380

IC contact e-mail YouleR@ninds.nih.gov

 

For Collaborator:  same as for M-CRADA notices

Collaborator Contact:

Collaborator Address:

Collaborator Phone Number:

Collaborator Fax:

Collaborator contact e-mail:

 

	NIH M-CRADA	Agreement Ref. No. 2013-0167	MODEL ADOPTED 2006
	Page 7 of 10	Confidential	Revised August 1, 2012

 

    	 

    	 

    

 

SUMMARY PAGE

 

Either
party may, without further consultation or permission,

release
this summary page to the public.

 

	TITLE OF M-CRADA:	 	Characterization of Proprietary Compounds from Lixte Biotechnology Holdings, Inc.
	 	 	 
	NIH Institute/Center (IC) IC Principal Investigator:	 	National Institute of Neurological Disorders and Stroke Richard J. Youle, Ph.D.
	 	 	 
	
        Collaborator:

        Collaborator Principal Investigator:
	 	Lixte Biotechnology Holdings, Inc. 

John S. Kovach, M.D.
	 	 	 
	TERM OF M-CRADA:	 	Four (4) years from the Effective Date.

 

ABSTRACT OF THE RESEARCH PLAN:

 

The Surgical Neurology Branch of the National
Institute of Neurological Disorders and Stroke of the National Institutes of Health will conduct research characterizing a variety
of compounds proprietary to Lixte Biotechnology Holdings, Inc., under a Materials Cooperative Research and Development Agreement.
The research will examine the compounds’ potential for anti-cancer activity, reducing neurologic deficit due to ischemia
and brain injury, and stabilizing catalytic function of misfolded proteins for inborn brain diseases.

 

	NIH M-CRADA	Agreement Ref. No. 2013-0167	MODEL ADOPTED 2006
	Page 8 of 10	Confidential	Revised August 1, 2012

 

    	 

    	 

    

 

APPENDIX A

 

RESEARCH PLAN

 

Background

Lixte Biotechnology Holdings, Inc.’s primary emphasis
is on developing drugs for cancer but its proprietary compounds also have potential for treating a variety of other diseases. The
Surgical Neurology Branch (SNB) has experience in researching brain tumors, neurological brain injury, and inborn diseases affecting
the brain, such as Gaucher’s disease, von Hippel-Lindau, and neurofibromatosis type II.

 

Overall Goal. The SNB would like to examine the Collaborator’s
compounds’ potential for anti-cancer activity, reduction of neurologic deficit due to ischemia and brain injury, and stabilization
of the catalytic function of misfolded proteins for inborn brain diseases.

 

Research

The SNB will characterize proprietary compounds from the Collaborator,
including but not limited to the following seven:

LB-100, LB-102, LB-113, LB-153, LB-157, LB-201, and LB-205.

Collaborator may provide additional proprietary compounds to
the SNB if the parties mutually agree in advance and the transfer is documented in writing.

 

The SNB may study one or more of the above compounds in in
vitro and in vivo (animal models) for the following effects:

 

		•	promoting anti-cancer activity alone or in combination with standard anti-cancer drugs and/or radiation for the treatment of
primary brain tumors and secondary (metastatic) brain tumors; specific cancers may include astrocytic tumors, oligodendroglial
tumors, medulloblastoma, meningeal tumors, hemangioblastomas, and brain mestastic tumors

 

		•	overcoming or mitigating the physiological phenomenon of multi-drug resistance, particularly of cancer cells to anti-cancer
drugs

 

		•	reducing neurological deficit due to cerebral ischemia and traumatic brain injury

 

		•	stabilizing the catalytic function of misfolded proteins due to genetic variants responsible for inborn diseases affecting
the brain, such as Gaucher’s disease, von Hippel-Lindau diseases and neurofibromatosis 2

 

	NIH M-CRADA	Agreement Ref. No. 2013-0167	MODEL ADOPTED 2006
	Page 9 of 10	Confidential	Revised August 1, 2012

 

    	 

    	 

    

 

APPENDIX B

 

EXCEPTIONS OR MODIFICATIONS TO THIS M-CRADA

Additions are noted as underline
and deletions are noted as strikeout.

 

Modify Article 20 as follows:

 

	Article 20.	This M-CRADA shall be effective upon execution by the Parties. The term of this M-CRADA is forty-eighttwelve (4812) months from execution. When the Research Plan is completed or forty-eighttwelve (4812) months has elapsed, whichever occurs first, or the M-CRADA is terminated, the Collaborator Research Material will be disposed of as directed by Collaborator.

 

	NIH M-CRADA	Agreement Ref. No. 2013-0167	MODEL ADOPTED 2006
	Page 10 of 10	Confidential	Revised August 1, 2012SCIENTIFIC
ADVISORY BOARD AGREEMENT

 

THIS AGREEMENT
(the “Agreement”) is made and entered into this 24th day of December, 2013 (the “Effective Date”)
between Lixte Biotechnology Holdings, Inc., 248 Route 25A No. 2, East Setauket, New York 11733 (hereinafter referred to as the
“Company”), and NDA Consulting Corp., an Arizona corporation, with offices at 9977 N. 90th Street, Suite 175, Scottsdale,
Arizona 85258 (hereinafter referred to as the “Consultant”).

 

WHEREAS,
the Company wishes to engage the Consultant to serve the Company as an Advisor for Clinical Development and provide this service
for the compensation and otherwise in accordance with the terms and conditions contained in this Agreement.

 

NOW, THEREFORE,
in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, accepted and agreed to, the Company and the Consultant, intending to be legally bound, agree to the terms set forth
below.

 

1.            TERM.

 

(a)          The
initial term of this Agreement is one (1) year from the Effective Date. The initial term will be extended for successive terms
of one (1) year on each anniversary date of the Effective Date, unless the Agreement is terminated as provided below. This Agreement
may be renewed or extended for any period as may be mutually agreed by the parties.

 

(b)          This
Agreement may be cancelled by either party for any reason by providing written notice to the other party not less than thirty (30)
days prior to the end of the initial term or any successive one (1) year term. Upon termination, Consultant shall return to the
Company or destroy all Concepts and Ideas and Confidential Information (as defined in Section 5 below) and copies thereof.

 

(c)          In
the event Dr. Von Hoff accepts an invitation from the Company to become Principal Investigator in a clinical trial conducted by
the Company, this Agreement shall immediately terminate and no further Services will be provided by Consultant pursuant to this
Agreement.

 

2.            SERVICES.

 

(a)          Consultant
agrees to cause its President, Dr. Von Hoff to be a member of and advise the Company’s SAB in the field of oncology research
and drug development under the terms and conditions herein provided (the “Services”). The Services shall only
be performed by Dr. Von Hoff personally and may not be assigned, subcontracted or otherwise delegated
without the prior written consent of the Company

 

    	 

    	 

    

 

(b)          The
Consultant represents and warrants to the Company that it is under no contractual or other restrictions or obligations which are
inconsistent with the execution of this Agreement, or which will interfere with the performance of its duties. Consultant represents
and warrants that the execution and performance of this Agreement will not violate any policies or procedures of any other person
or entity for which it performs consulting services concurrently with those performed herein.

 

3.            COMPENSATION.

 

(a)          Subject
to the provisions hereof, the Company shall pay the Consultant four thousand dollars ($4,000) per calendar quarter, for providing
the Services to the Company (the “Consulting Fee”) for up to a cumulative amount of 4 hours per quarter. As
additional compensation, the Company shall provide Dr. Von Hoff a grant of options to purchase an aggregate of shares of Lixte
with the options vesting as follows: 25,000 options vesting six, eighteen, thirty, and forty two months after the date of this
agreement so long as Dr. Von Hoff is continuing as Advisor for Clinical Development on those dates. The options shall be for five
years.

 

(b)          The
Consulting Fee shall be paid within thirty (30) days of the receipt by the Company of the Consultant’s invoice for Services.
The grant of stock or stock options shall be made to Dr. Von Hoff as soon as practicable after the Effective Date.

 

(c)          The
Consultant shall be entitled to reimbursement of two hundred fifty dollars ($250) per hour for travel time (not to exceed one thousand
five hundred dollars ($1,500) per day) on approved Company business. The Consultant shall also be entitled to prompt reimbursement
for preapproved, actual travel and out-of-pocket business expenses incurred in the performance of its Services. The Company shall
reimburse Consultant within thirty (30) days of receipt by the Company of the Consultant’s statements or receipts for such
expenses. For air travel of three (3) hours or more, Consultant shall be entitled to First Class Airfare.

 

(d)          Unless
otherwise notified by the Consultant, the Company shall make payment of the Consulting Fee and reimbursement of travel and out-of-pocket
expenses in the name of the Consultant and send the payments directly to:

 

NDA Consulting Corp.

c/o MCS Biotech Resources,
LLC

9977 N. 90th Street,
Suite 175

Scottsdale, AZ 85258

 

Stock or
stock options issued in the name of Dr. Von Hoff shall be sent to the same address.

 

    	2

    	 

    

 

(e)          The
Consultant agrees that all Services rendered will be as an independent contractor and that this Agreement does not create an employer-employee,
agency, joint venture, or partnership relationship between the Consultant and the Company. The Consultant shall have no right to
receive any employee benefits, including, but not limited to, health and accident insurance, retirement, life insurance, sick leave
and/or vacation. The Consultant agrees to pay all taxes, including self-employment taxes due in respect of the Consulting Fee and
to indemnify the Company in the event the Company is required to pay any such taxes as a direct result of actions taken by the
Consultant.

 

4.            COMPANY
OBLIGATIONS.

 

(a)          The
Company shall provide the Consultant with all information and materials that are necessary to enable Consultant to perform the
Services. The Company acknowledges and agrees that such information and materials will be used, and the accuracy and completeness
of such information and materials relied upon, by the Consultant as the basis for providing the Services.

 

(b)          Company
agrees that Consultant’s services are provided without representation or warranty or any kind. Company acknowledges that
drug development carries inherent risks and that no particular work product or business result is guaranteed under this Agreement.
Except with respect to Section 5, the Company agrees that Consultant’s monetary liability for any breach of this Agreement
shall in no event exceed the amount of cash compensation paid to Consultant under this Agreement. Company hereby releases Consultant
from any monetary liability to the extent it may exceed such amount. In addition, Company agrees to indemnify, defend and hold
Consultant harmless from and against any losses, costs, claims, damages, liabilities or expense (including reasonable attorneys’
and professional fees and other expenses of litigation) (collectively, “Liabilities”) arising directly or indirectly
out of or in connection with third party claims, suits, actions, demands or judgments, relating to services provided by Consultant
under this Agreement.

 

(c)          The
Company agrees not to use the Consultant’s name in any publications or other written material, or otherwise use Consultant’s
name in any manner whatsoever unless, in each case, the Company obtains the prior written consent of the Consultant. Unless otherwise
notified by Consultant, all such requests should be directed to:

 

MCS Biotech Resources,
LLC

9977 N. 90th Street,
Suite 175

Scottsdale, AZ 85258

Telephone number: (480)
268-2000

Facsimile number: (480)
268-2001

 

5.            PROPRIETARY
RIGHTS.

 

(a)          Definitions.
For the purpose of this Section 5, the terms set forth below shall have the following meanings:

 

    	3

    	 

    

 

(i)          Concept
and Ideas. For the purpose of this Agreement, “Concepts and Ideas” shall mean those concepts and ideas disclosed
by the Company to the Consultant or which are first developed by the Consultant during the course of the performance of Services
hereunder and which relate to the Company’s past, present, or prospective business activities, services, and products, all
of which shall remain the sole and exclusive property of the Company. The Consultant shall have no publication rights and all of
the same shall belong exclusively to the Company.

 

(ii)         Confidential
Information. For the purposes of this Agreement, “Confidential Information” shall mean and collectively include
all information relating to the business, plans and/or technology of the Company including, but not limited to technical information,
including inventions, methods, plans, processes, specifications, characteristics, assays, raw data, scientific pre-clinical or
clinical data, records, databases, formulations, clinical protocols, equipment design, know-how, experience, and trade secrets.

 

Notwithstanding
the foregoing, the term “Confidential Information” shall not include any information which: (x) can be demonstrated
to have already been publicly known or available or generally known in the trade or business of the Company prior to the date of
the disclosure to the Consultant, (y) can be demonstrated to have been rightfully in the possession of the Consultant prior to
the disclosure of such information to the Consultant, or (z) is required to be disclosed by Consultant as a matter of law or by
a judicial or governmental order or requirement.

 

(b)          Non-Disclosure
to Third Parties. Except as may be required for the Consultant to perform the Services, the Consultant shall not, at any time
now or in the future, directly or indirectly, use, publish, disseminate or otherwise disclose any Confidential Information or Concepts
and Ideas to any third party without the prior written consent of the Company.

 

(c)          Patents.
The Consultant agrees that the Company is and shall remain the exclusive owner of the Confidential Information and Concepts and
Ideas. Any interest in patents, patent applications, inventions, technological innovations, trade names, trademarks, service marks,
copyrights, copyrightable works, developments, discoveries, designs, processes, formulas, know-how, data and analysis which the
Consultant may develop as a direct result of rendering Services to the Company under this Agreement (collectively the “Developments”),
shall: (i) promptly be brought to the attention of the Company by the Consultant and (ii) belong exclusively to the Company. No
license or conveyance of any such rights to the Consultant is granted or implied under this Agreement.

 

(d)          Assignment.
The Consultant hereby assigns and, to the extent any such assignment cannot be made at present, hereby agrees to assign to the
Company any Developments. The Consultant will execute all documents and perform all lawful acts, which the Company considers reasonably
necessary or advisable to secure its rights hereunder.

 

In the event
the company is unable for any reason to secure the Consultant’s signature to any document required to apply for or execute
any patent, copyright or other application with respect to any Developments, the Consultant hereby irrevocably designates and appoints
the Company and its duly authorized officers and agents as the Consultant’s attorneys-in-fact to act for and on behalf of
the Consultant, for the sole purpose of executing and filing any such document.

 

    	4

    	 

    

 

6.           EQUITABLE
RELIEF. The Consultant agrees that any breach of Section 5 above by it would cause irreparable damage to the Company and that,
in the event of such breach, the Company shall have, in addition to any and all remedies of law, the right to an injunction, specific
performance or other equitable relief to prevent the violation or threatened violation of the Consultant’s obligations hereunder.

 

7.           WAIVER.
Any waiver by either party of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any
subsequent breach of the same or any other provision hereof. All waivers by either party shall be in writing.

 

8.           SEVERABILITY;
REFORMATION. If a court or other lawful authority finds any provision of this Agreement to be invalid and unenforceable, the remaining
provisions are severable, and will not be affected by that finding. If a court or lawful authority finds any provision of this
Agreement to be excessively broad as to duration, geographical scope, activity or subject matter, that provision will be construed
to make it enforceable to the extent possible under the applicable law then in effect.

 

9.           ASSIGNMENT.
The Company shall have the right to assign its rights and obligations under this Agreement to a related party, which assumes the
Company’s obligations hereunder. The Consultant shall not have the right to assign its rights or obligations under this Agreement
without the prior written consent of the Company, which consent shall not be unreasonably withheld.

 

10.         HEADINGS.
Headings and subheadings are for convenience only and shall not be deemed to be a part of this Agreement.

 

11.         AMENDMENTS.
This Agreement may be amended or modified, in whole or in part, only by an instrument in writing signed by all parties hereto.

 

12.         NOTICES.
Any notices or other communications required hereunder shall be in writing and shall be deemed effective when (a) hand-delivered
with receipt acknowledged, (b) delivered by a nationally recognized overnight delivery service with receipt acknowledged, (c) sent
by confirmed facsimile, or (d) three (3) days after mailing, by certified or registered first class mail, postage prepaid, return
receipt requested; in each case, addressed to the parties at their addresses specified in the preamble of this Agreement or to
such other address as a party hereto shall designate upon written notice to the other party.

 

13.         COUNTERPARTS.
This Agreement may be executed in two or more counterparts, each of which shall constitute an original and all of which shall be
deemed a single agreement.

 

    	5

    	 

    

 

14.         GOVERNING
LAW. This Agreement shall be construed in accordance with and governed for all purposes by the laws of the State of Arizona.

 

15.         SURVIVAL.
The provision of Sections 3, 4, 5, 6, 8 and 14 of this Agreement shall survive the expiration of the Term or the termination of
this Agreement. This Agreement supersedes all prior agreements, written or oral, between the Company and the Consultant relating
to the subject matter of this Agreement.

 

EXECUTED,
under seal, effective as of the Effective Date.

 

	Lixte Biotechnology Holdings, Inc.	 	NDA Consulting Corp.
	 	 	 
	/s/ John S. Kovach	 	 
	John S. Kovach, M.D.	 	Daniel D. Von Hoff, M.D.
	 	 	President
	 	 	 
	 	 	Federal ID Tax Number 26-0348104

 

    	6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]